SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is currently seeing intense debate as investors weigh aggressive institutional Ethereum accumulation against significant share price underperformance compared to broader crypto markets. Community sentiment is deeply polarized, with many retail traders expressing frustration over Tom Lee's leadership and dilution tactics while bulls continue to focus on the long-term potential of asset tokenization and upcoming clarity legislation.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased volatility and investor attention following reports that Berkshire Hathaway has exited its entire position in the stock. While some investors express concern over this abrupt move by a major institutional holder, many in the community view the resulting dip as a potential buying opportunity, emphasizing the company's long-term operational strengths and its ongoing integration of AI into daily workflows.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is experiencing significant trading activity driven by its expanding role in AI and EV chip reliability testing, with investors closely watching its revenue growth and capacity expansion in Malaysia. The community is actively debating the company's valuation relative to larger sector peers, with many focusing on the potential for a fundamental re-rating amid strong order flow and a relatively small float.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility driven by intense speculation surrounding Brad Jacobs' aggressive roll-up strategy and the potential for a short squeeze, with the community closely tracking the stock's consolidation efforts and its pivot toward becoming a major player in the industrial building products supply chain. Investors remain divided, weighing the risks of continued dilution and macro-economic headwinds against long-term conviction in management's track record and the potential for rapid valuation re-ratings following strategic acquisitions.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors prepare for upcoming clinical data presentations at the AUA Annual Meeting, with the community focused on the durability of CAN-2409 and its potential as a practice-changing therapy. Discussions center on the stock's long-term value, with active debates occurring between bulls anticipating a premium acquisition and bears citing concerns over cash runway and timing.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending following the announcement of a new agreement with a major group purchasing organization, which secures commercial payer coverage for TONMYA across millions of U.S. lives. While investors are closely monitoring this commercial expansion and upcoming earnings, community discussion remains divided between bullish sentiment regarding the drug's growth potential and concerns over historical dilution and the company's capital management strategy.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense volatility and aggressive community debate following a major registered direct offering of 400 million dollars and executive leadership changes, which have fueled both bullish sentiment regarding institutional validation and bearish concerns over dilution. Traders are heavily fixated on the stock's massive recent price swings, with many actively discussing potential entry points at lower technical support levels while others argue over the company's long-term commercial execution and valuation.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

SolarEdge is attracting significant attention as investors pivot toward its potential role in AI data center energy infrastructure, moving beyond its traditional solar-only narrative. The stock is currently seeing heightened trading activity and volatility as the community debates whether this strategic shift marks the beginning of a sustainable new energy cycle or remains a speculative sentiment-driven rotation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is seeing significant volatility as market participants weigh geopolitical news regarding export deals against the anticipation of earnings. Community discussion remains heavily focused on potential post-earnings momentum and the stock's role as a primary liquidity driver for the broader AI sector.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is currently a focal point of market conversation due to its complex balancing act between strong consumer travel demand and the financial headwinds caused by escalating geopolitical tensions. Community sentiment is deeply divided, with some investors highlighting the company's refinery-driven fuel hedging as a strategic advantage, while others remain wary of broader sector risks, supply chain instability, and the impact of fluctuating oil prices on future profit margins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook

ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence. 

ANIP Valuation: Does 9.8x Forward P/E Offer Upside?

ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales. 

ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge

Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.

ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million

Key PointsSold 228,895 shares of ANI Pharmaceuticals; estimated trade value $17.87 million (based on average Q1 2026 pricing...

ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised

ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.

Zacks.com featured highlights include ANI, Cummins and Seadrill 

ANI, Cummins and Seadrill have been highlighted in this Screen of The Week article.


3 Stocks Showing Powerful Earnings Acceleration This May 

ANIP, CMI and SDRL stand out in May as earnings acceleration stocks, with rising EPS growth trends signaling potential share price momentum. 

ANI (ANIP) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of +60.16% and +15.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Current Price	$78.01
Prev Close	$79.58
Open	$79.28
Dividend Yield	0.00%
50-Day Moving Average	$77.50
Beta	0.63
Avg. Volume	335,584.25
PE Ratio	20.19

52-Week High	$99.50
52-Week Low	$56.71
Market Capitalization	$1.81B
EPS (Annual)	$3.32
Price to Book	3.24
Revenue Per Employee	$910,686.60

ANIP
ANI Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANIP News

ANIPANI Pharmaceuticals Inc